Leland Stanford Junior University

The United States Government As Represented by the Department of Veterans Affairs

Other

Stuart Barry Goodman

Yaser Shanjani

David Myung

Curtis W Frank

Lampros Kourtis

Yunzhi Peter Yang

Dennis R Carter

Laura Hartmann

Tzuhua Dennis Lin

Fu-Kuo Chang

Everett Hurteau Meyer

Fan Yang

Magdiel Pérez Cruz

Chi-Chun Pan

Hasan Yildiz

Sai-Wen Tang

Michael Gerard Keeney

Jukka Pajarinen

An engineered medical device for treatment of osteonecrosis is provided where the size, porosity and ceramic content of the device can be personalized based on an individual patient's anatomical and physiological condition. The device distinguishes different segments mimicking anatomically-relevant cortical and cancellous segments, in which the cortical segments of the device can sustain mechanical loading, and the cancellous segment of the device can promote bone ingrowth, osteogenesis and angiogenesis.

Customized load-bearing and bioactive functionally-graded implant for treatment of osteonecrosis

Provided are compositions and methods for production of anti-inflammatory cytokines, growth factors, or chemokines. Provided are nucleic acids (e.g., expression vectors) that include an NF&#x3ba;B inflammation response element operably linked to a nucleotide sequence encoding an anti-inflammatory cytokine (e.g., IL-4). In some cases, the nucleic acid is an expression vector selected from: a linear expression vector, a circular expression vector, a plasmid, and a viral expression vector. Also provided are cells (e.g., mesenchymal stem cells&#x2014;MSCs) comprising a nucleic acid that includes an NF&#x3ba;B inflammation response element operably linked to a nucleotide sequence encoding an anti-inflammatory cytokine. In some cases, the nucleic acid is integrated into the cell's genome. Also provided are methods for treating an individual having an inflammation-associated ailment, which can include administering an MSC to the individual, where the MSC includes an NF&#x3ba;B inflammation response element operably linked to a nucleotide sequence encoding an anti-inflammatory cytokine.

Mesenchymal stem cells expressing anti-inflammatory cytokines and methods of use

Mesenchymal stromal cells are engineered to express a chimeric antigen receptor (CAR), that specifically binds a marker of activated myeloid cells, including without limitation folate receptor beta; and are administered to an individual for treatment of inflammation at sites characterized by the presence of activated myeloid cells.

Systemic targeting of inflammatory sites and enhanced immunomodulatory function by introducing the chimeric antigen receptor (CAR) into mesenchymal stem cells for inflammatory and autoimmune diseases

A bone implant primer is provided. A biodegradable hydrogel component is provided. A plurality of biomolecule release depots are dispersed within the biodegradable hydrogel component wherein the plurality of biomolecule release depots comprise biomolecules for aiding implant osseointegration or biomolecules for mitigation of foreign body response. Different biomolecules may be released by the microspheres at different times.

Injectable hydrogel system to modulate host response at bone implant interface

An arthroplasty device is provided having an interpenetrating polymer network (IPN) hydrogel that is strain-hardened by swelling and adapted to be held in place in a joint by conforming to a bone geometry. The strain-hardened IPN hydrogel is based on two different networks: (1) a non-silicone network of preformed hydrophilic non-ionic telechelic macromonomers chemically cross-linked by polymerization of its end-groups, and (2) a non-silicone network of ionizable monomers. The second network was polymerized and chemically cross-linked in the presence of the first network and has formed physical cross-links with the first network. Within the IPN, the degree of chemical cross-linking in the second network is less than in the first network. An aqueous salt solution (neutral pH) is used to ionize and swell the second network. The swelling of the second network is constrained by the first network resulting in an increase in effective physical cross-links within the IPN.

Hydrogel arthroplasty device

The present invention discloses a side-dependent prosthetic device. The side-dependent prosthetic device is a composite prosthetic device with a longitudinal direction. The composite prosthetic device includes a plurality of plies wherein each ply being composed of a plurality of reinforced fibers aligned in a ply orientational angle &thgr;i relative to the longitudinal direction of the prosthetic device, where i&equals;1,2,3, . . . ,N and N being the number of the plies. The plurality of plies are laminated together for forming the prosthetic device wherein the ply orientational angles being arranged such that &thgr;1&plus;&thgr;2&plus;&thgr;3&plus; . . . &plus;&thgr;,&minus;0 thus forming an unbalanced composite prosthetic device. In another preferred embodiment, the ply orientational angles &thgr;i forming a sequence which is represented by ((&thgr;,/&thgr;,),),where a first ply with orientational angle &thgr;,being followed by a second ply with orientational angle &thgr;,wherein such a sequence repeated n-times and arranged to be symmetrical to a mid-plane, wherein &thgr;,being an angle close to &minus;10,and &thgr;,being an angle close to &minus;20,.

Unbalanced prosthetic device for providing side-dependent twisting-rotational axial-loading coupling

Growing community of inventors

Los Altos, CA, United States of America

Stuart Barry Goodman